Please use this identifier to cite or link to this item:
Title: Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Author: Pastick, Katelyn A.
Okafor, Elizabeth C.
Wang, Fan
Lofgren, Sarah M.
Skipper, Caleb P.
Nicol, Melanie R.
Pullen, Matthew F.
Rajasingham, Radha
McDonald, Emily G
Lee, Todd C.
Schwartz, Ilan S.
Kelly, Lauren E.
Lother, Sylvain A.
Mitjà Villar, Oriol
Letang, Emilio
Abassi, Mahsa
Boulware, David R.
Keywords: SARS-CoV-2
Parasitologia mèdica
Medical parasitology
Issue Date: 15-Apr-2020
Publisher: Oxford University Press; Infectious Diseases Society of America
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Note: Reproducció del document publicat a:
It is part of: Open Forum Infectious Diseases, 2020, vol. 7, num. 4
Related resource:
ISSN: 2328-8957
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
Pastik_KA_Open_Forum_Infect_Dis_2020.pdf207.42 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons